Lund, SE — October 16, 2025 — Leads & Copy — Alligator Bioscience (Nasdaq Stockholm:ATORX)(STO:ATORX) will publish its interim report for the third quarter 2025 on Thursday, 23 October 2025, at 8:00 a.m. CEST. The company will host a webinar and conference call for investors, analysts, and media at 3:00 p.m. CEST / 9:00 a.m. EDT on the same day, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, followed by a Q&A session.
Attendees are required to register in advance via a provided link and can submit questions in advance to ir@alligatorbioscience.com. The full report will be available upon publication on Alligator’s website.
Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The Company’s lead drug candidate mitazalimab is currently ready for Phase 3 development. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.
Søren Bregenholt, CEO
E-mail: soren.bregenholt@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
Johan Giléus, CFO
E-mail: johan.gileus@alligatorbioscience.com
Phone: +46 (0) 46 540 82 00
Source: Alligator Bioscience
